The Roanoke Times: Commentary: AARP has a massive conflict of interest in drug price debate
AARP has weighed in as the 800-pound gorilla in Virginia’s drug pricing debate, lending its weight to a so-called Prescription Drug Affordability Board (PDAB) that would be empowered to impose price controls on medicines. But it’s crucial for legislators and the governor to understand that AARP advocates not on behalf of seniors but rather on behalf of its corporate partner and principal funding source — UnitedHealth. AARP’s own survey research shows that insurance-related costs such…
Learn More